Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.69 |
| ▸ | SRC | P12931 | 4/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038197 | 0.92 | EGFR (0.82) | EGFRERBB2SRCKDRKCNH2 | |
| SCHEMBL4207635 | 0.92 | EGFR (0.65) | EGFRERBB2SRCKDRKCNH2 | |
| SCHEMBL4036733 | 0.90 | ERBB2 (0.84) | EGFRERBB2SRCKCNH2 | |
| SCHEMBL4032085 | 0.89 | EGFR (0.69) | EGFRERBB2SRCKDRKCNH2 | |
| Hydrochloric Acid SCHEMBL4031635 | 0.89 | EGFR (0.65) | EGFRERBB2SRCKDRKCNH2 | |
| SCHEMBL4032523 | 0.87 | EGFR (0.75) | EGFRERBB2SRCKDRKCNH2 | |
| SCHEMBL4038969 | 0.87 | EGFR (0.69) | EGFRERBB2SRCKDRKCNH2 | |
| SCHEMBL4037101 | 0.85 | EGFR (0.81) | EGFRERBB2KCNH2 | |
| SCHEMBL4034225 | 0.85 | EGFR (0.78) | EGFRERBB2KCNH2 | |
| SCHEMBL4036185 | 0.85 | EGFR (0.67) | EGFRERBB2SRCKDRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885ERBB2 1/4885SRC 111/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885SRC 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.